BSI-001

BSI-001 (5G9) 是一种 HER2 靶向抗体,在 HER2 阳性癌细胞中与 Trastuzumab (MS-U55108) 联用时抑制细胞增殖、迁移,诱导细胞凋亡 (Apoptosis) 和 PARP 切割,并抑制 HER2 介导的下游信号通路(包括 EGFR、HER3、AKT 和 ERK 的磷酸化);在胃癌、乳腺癌动物模型中,BSI-001 与 Trastuzumab 联用展现出协同抗肿瘤功效,可用于 HER2 阳性乳腺癌与 HER2 过表达胃癌的研究。
BSI-001
产品编号: MS-Z30703
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价

产品描述

BSI-001 (5G9) 是一种 HER2 靶向抗体,在 HER2 阳性癌细胞中与 Trastuzumab (MS-U55108) 联用时抑制细胞增殖、迁移,诱导细胞凋亡 (Apoptosis) 和 PARP 切割,并抑制 HER2 介导的下游信号通路(包括 EGFR、HER3、AKT 和 ERK 的磷酸化);在胃癌、乳腺癌动物模型中,BSI-001 与 Trastuzumab 联用展现出协同抗肿瘤功效,可用于 HER2 阳性乳腺癌与 HER2 过表达胃癌的研究。

生物实验数据

生物活性 BSI-001 (5G9) is a HER2-targeting antibody that, when combined with Trastuzumab (MS-U55108) in HER2-positive cancer cells, inhibits cell proliferation and migration, induces apoptosis and PARP cleavage, and suppresses HER2-mediated downstream signaling pathways (including phosphorylation of EGFR, HER3, AKT, and ERK); in gastric cancer and breast cancer animal models, BSI-001 combined with Trastuzumab exhibits synergistic antitumor efficacy, and BSI-001 can be used for research on HER2-positive breast cancer and HER2-overexpressing gastric cancer.
体外研究
(In Vitro)

BSI-001 可与过表达 HER2 的 BT-474 和 SK-BR-3 细胞强烈结合。
BSI-001 (100 nM, serially diluted; 3-6 days) 单独使用时可微弱抑制 HER2 阳性癌细胞的增殖,但与 Trastuzumab (MS-U55108) 以 1:1 固定剂量比例联合使用时,其可在多种 HER2 阳性癌细胞系中发挥强效的协同增殖抑制作用。
BSI-001 (72 h) 与 Trastuzumab 联用可强效抑制 BT-474 细胞迁移。
BSI-001 (100 nM; 72 h) 联合 Trastuzumab 在 BT-474 细胞中诱导晚期细胞凋亡、诱导 PARP 切割。
BSI-001 (100 nM; 3 days) 与 Trastuzumab 联用可降低 BT-474 细胞中总 HER2 蛋白水平,并抑制 HER2 介导的下游信号通路 (包括 EGFR、HER3、AKT 和 ERK 的磷酸化)。

Cell Viability Assay

Cell Line: HER2-positive human breast cancer BT-474, SK-BR-3, AU-565 cells; NCI-N87 cells
Concentration: 100 nM (single agent for SK-BR-3, AU-565, NCI-N87); serially diluted (alone or 1:1 fixed-dose ratio with trastuzumab for BT-474)
Incubation Time: 6 days (BT-474); 3 or 6 days (SK-BR-3, AU-565, NCI-N87)
Result: Alone exhibited weak inhibition of BT-474 cell proliferation.
In combination with Trastuzumab, showed substantially enhanced BT-474 cell proliferation inhibition compared to single agents.
Showed stronger synergism between 5G9 and trastuzumab.
In SK-BR-3, AU-565, and NCI-N87 cells, the combination of 5G9 and trastuzumab reduced cell viability more effectively.

Apoptosis Analysis

Cell Line: HER2-positive human breast cancer BT-474 cells
Concentration: 100 nM
Incubation Time: 72 h
Result: Resulted in a significantly lower number of viable BT-474 cells and a higher level of late-stage apoptosis combinated with Trastuzumab, compared to the trastuzumab-pertuzumab combination.

Western Blot Analysis

Cell Line: HER2-positive human breast cancer BT-474 cells
Concentration: 10 μg/mL
Incubation Time: 3 days
Result: Induced significantly increased cleavage of PARP, a marker of apoptosis combinated with Trastuzumab.

Western Blot Analysis

Cell Line: HER2-positive human breast cancer BT-474 cells
Concentration: 100 nM
Incubation Time: 3 days
Result: Reduced total and phosphorylated HER2 protein levels, and also reduced phosphorylated levels of EGFR, HER3, AKT, and ERK (total protein levels of these targets remained unchanged) combinated with Trastuzumab.
体内研究
(In Vivo)

BSI-001 (5-15 mg/kg; i.p.; twice weekly) 在 NCI-N87 胃癌异种移植模型中与Trastuzumab 联用具有强效协同抗肿瘤活性。
BSI-001 (3 mg/kg; i.p.; twice weekly) 在 BT-474 乳腺癌异种移植物模型中与 Trastuzumab 联用具有强效协同抗肿瘤活性。

Animal Model: NOD SCID (6 to 8-week-old; subcutaneous inoculation of NCI-N87 cells)
Dosage: 5 mg/kg (monotherapy, TGI); 5 mg/kg + 5 mg/kg Trastuzumab (combination, TGI); 15 mg/kg + 15 mg/kg Trastuzumab (combination, tumor eradication)
Administration: i.p.; twice weekly
Result: Resulted in a tumor growth inhibition (TGI) of 18.16%.
Achieved a TGI of 98.31%, with a day 22 mean tumor volume of 8.75 mm3, which was significantly higher than 15 mg/kg Trastuzumab monotherapy.
Eradicated tumors in 6 out of 7 mice, with no significant tumor regrowth observed through day 63, whereas Trastuzumab plus pertuzumab at the same dose showed tumor progression.
Showed a significantly higher TGI than the Trastuzumab plus pertuzumab combination at the same dose.
Animal Model: NOD SCID (6 to 8-week-old; subcutaneous inoculation of BT-474 cells)
Dosage: 3 mg/kg + 3 mg/kg Trastuzumab
Administration: i.p.; twice weekly
Result: Resulted in a TGI of 47%, which was significantly higher than the 24% TGI achieved by the same-dose combination of Trastuzumab plus pertuzumab.
Reduced final mean tumor mass significantly compared to the pertuzumab combination group.

化学信息

别名 5G9

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础